Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
Last month, COMPASS reported that COMP360 was well tolerated when administered to healthy adult volunteers with support from specially trained therapists in a randomised placebo-controlled trial.